| Followers | 17 |
| Posts | 624 |
| Boards Moderated | 0 |
| Alias Born | 11/21/2014 |
Friday, August 21, 2020 10:15:05 PM
RE: This is big!
Approval is at minimum 2-4 weeks out, being optimistic about timetables. The leaked document of the 21 patients has yet to be peer reviewed. Seeing that the document had contained some errors, it was still in preliminary stages of being drafted and reviewed before being submitted. The peer review process takes on average 3 weeks after official submission.
After reading Dr. Javitt's impressive bio, he would not be one to rush data without a rigorous process of scrutiny. You don't make it to the prestigious level of being top 1% most cited researchers in the world by not following proper protocol.
Approval is at minimum 2-4 weeks out, being optimistic about timetables. The leaked document of the 21 patients has yet to be peer reviewed. Seeing that the document had contained some errors, it was still in preliminary stages of being drafted and reviewed before being submitted. The peer review process takes on average 3 weeks after official submission.
After reading Dr. Javitt's impressive bio, he would not be one to rush data without a rigorous process of scrutiny. You don't make it to the prestigious level of being top 1% most cited researchers in the world by not following proper protocol.
*I probably own shares of this stock. All posts are made in my opinion only and are not investing advice.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
- Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod • AllPennyStocks.com • 05/22/2025 04:49:00 PM
